Elena Naumovska completed her PhD and post-doctoral research in 3D tissue engineering and iPSC differentiation, where she invented the microtissue technology behind StemX Bio. She co-founded the company to turn this science into a product and now serves as Chief Scientific Officer. From the lab in Leiden, she leads research and development of human pancreatic microtissues, New Approach Methodologies which let drug developers test compounds on human tissue rather than animal models. Her work centers on one goal, micro tissues for macro impact, human-relevant data from the plate to the clinic.